Shares of CANbridge Pharmaceuticals (HKG:1228) surged 15.95% during intraday trading on Monday, as investors reacted positively to the company's latest financial results. The pharmaceutical firm announced a return to profitability in the first half of 2025, marking a significant turnaround from the previous year's losses.

According to a Hong Kong bourse filing on Sunday, CANbridge reported an attributable profit of 59.2 million yuan for the first half of 2025, reversing the 247.3 million yuan loss recorded in the same period last year. Earnings per share stood at 0.14 yuan, compared to a loss of 0.58 yuan in the prior year. However, it's worth noting that the company's revenue decreased to 22.2 million yuan from 44.8 million yuan in the previous year.

The market's enthusiastic response to CANbridge's financial turnaround highlights investors' optimism about the company's future prospects. Despite the revenue decline, the return to profitability suggests that the pharmaceutical firm's cost-cutting measures or strategic shifts may be paying off. As the healthcare sector continues to evolve, particularly in the wake of global health challenges, companies like CANbridge that can demonstrate financial resilience are likely to attract increased investor attention.